Adam Simmons, MPH: Promise in Potential New Frontline Schizophrenia Treatment


Telemedicine could be something that is still used, even after the COVID-19 pandemic is over.

It has proven difficult to find new frontline treatments for schizophrenia, often due to the potential side effects of existing treatment.

For example, while effective, olanzapine can lead to substantial weight gain in patients, preventing the medication from having a broader reach.

However, a potential new treatment in ALKS 3831 could 1 day become that frontline treatment, especially for younger schizophrenia patients.

ALKS 3831 is a combination therapy of samidorphan and olanzapine and has been tested to target weight gain profiles of users in recent clinical trials.

The success of the trials has Alkermes officials, developers of the promising drug, hopeful it may eventually have an impact treating this patient population.

The once-daily treatment has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of Nov. 15, 2020 by the US Food and Drug Administration (FDA).

In an interview with HCPLive®, Adam Simmons, MPH, Director of Clinical Program Management, Alkermes, explained the impact the treatment could have it is ultimately approved by the FDA.

Simmons also discussed how some of the telemedicine practices implemented during the coronavirus disease 2019 (COVID-19) pandemic could continue to be utilized in clinical research even after the pandemic is over.

Related Videos
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
Depression Screening: Challenges and Solutions at the Primary Care Level
What Should the American Academy of Physician Associates Focus on in 2025?
Danielle O'Laughlin, PA-C, MS: Navigating Long-Term Risks, Family Planning in PCOS
HCPLive Five at APA 2024 | Image Credit: HCPLive
John M. Oldham, MD: A History of Personality Disorder Pathology
Franklin King, MD: Psychedelic Therapy History, Advances, and Hurdles
Robert Weinrieb, MD: Psychiatry-Hepatology Approach for Alcohol-Related Liver Disease
© 2024 MJH Life Sciences

All rights reserved.